within Pharmacolibrary.Drugs.ATC.J;

model J05AR28
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR28</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) used in combination for the treatment of HIV-1 infection. The fixed-dose combination is classified under ATC code J05AR28 and is intended to suppress viral replication in HIV-positive individuals. Both drugs are approved and used within antiretroviral therapy regimens but have largely been replaced by newer, less toxic alternatives in high-income settings. The fixed-dose combination may still be used in resource-constrained settings.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic studies found for the fixed-dose combination of stavudine and lamivudine. Below are rough estimated parameters based on published PK data for the individual drugs in healthy adults after oral administration.</p><h4>References</h4><ol><li><p>Foster, RH, &amp; Faulds, D (1998). Abacavir. <i>Drugs</i> 55(5) 729–738. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199855050-00018&quot;>10.2165/00003495-199855050-00018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9585869/&quot;>https://pubmed.ncbi.nlm.nih.gov/9585869</a></p></li><li><p>Panhard, X, et al., &amp; Mentré, F (2007). Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. <i>European journal of clinical pharmacology</i> 63(11) 1019–1029. DOI:<a href=&quot;https://doi.org/10.1007/s00228-007-0337-x&quot;>10.1007/s00228-007-0337-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17694300/&quot;>https://pubmed.ncbi.nlm.nih.gov/17694300</a></p></li><li><p>Monif, T, et al., &amp; Biswal, S (2007). A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers. <i>Clinical therapeutics</i> 29(12) 2677–2684. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2007.12.028&quot;>10.1016/j.clinthera.2007.12.028</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18201583/&quot;>https://pubmed.ncbi.nlm.nih.gov/18201583</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR28;
